Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options

Rhea-AI Filing Summary

Aura Biosciences director Teresa Marie Bitetti received new equity awards as part of her compensation. She was granted 15,000 restricted stock units, each representing one share of common stock, and 30,000 stock options with an exercise price of $6.21 per share.

The RSUs and options each vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to her continued service. After the grant, she holds 36,000 shares of common stock directly, plus the newly awarded 30,000 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bitetti Teresa Marie

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	--
Grant/Award	Common Stock	15,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct, null); Common Stock — 36,000 shares (Direct, null)

Footnotes (1)

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

Key Figures

RSU grant size: 15,000 units Option grant size: 30,000 options Option exercise price: $6.21 per share +3 more

6 metrics

RSU grant size 15,000 units Restricted stock units granted to director on June 11, 2026

Option grant size 30,000 options Stock options granted to director on June 11, 2026

Option exercise price $6.21 per share Exercise price for 30,000 stock options

Options expiration June 11, 2036 Expiration date of stock options grant

Shares held after grant 36,000 shares Director’s direct common stock holdings after award

Underlying shares for options 30,000 shares Common shares underlying the stock option grant

Key Terms

restricted stock unit ("RSU") award, 2021 Stock Option and Incentive Plan, Stock Option (Right to Buy), exercise price, +1 more

5 terms

restricted stock unit ("RSU") award financial

"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."

2021 Stock Option and Incentive Plan financial

"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of the Issuer's stockholders financial

"the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 04:31 PM Accepted by SEC EDGAR 06/15/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bitetti Teresa Marie

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,000(1)	A	$0	36,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.21	06/11/2026		A		30,000		(2)	06/11/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

2. This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

	/s/ Conor Kilroy, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aura Biosciences (AURA) report for Teresa Marie Bitetti?

Aura Biosciences reported that director Teresa Marie Bitetti received equity awards. She was granted 15,000 restricted stock units and 30,000 stock options as compensation, with all awards vesting on specific future dates tied to her continued service.

How many Aura Biosciences (AURA) RSUs did Teresa Marie Bitetti receive?

Teresa Marie Bitetti received 15,000 restricted stock units from Aura Biosciences. Each RSU represents one share of common stock and will vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, if she continues serving.

What are the terms of Teresa Marie Bitetti’s Aura Biosciences stock options?

She received 30,000 stock options to buy Aura Biosciences common stock at $6.21 per share. These options vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting and expire on June 11, 2036, subject to continued service.

How many Aura Biosciences shares does Teresa Marie Bitetti own after this Form 4?

Following the equity award, Teresa Marie Bitetti directly holds 36,000 shares of Aura Biosciences common stock. This figure reflects her position after receiving 15,000 new RSUs, which convert to shares upon vesting, in addition to existing holdings reported.

When do Teresa Marie Bitetti’s Aura Biosciences RSUs vest?

The RSUs vest in full on the earlier of June 11, 2027 or the next annual meeting of Aura Biosciences stockholders. Vesting is conditioned on her continued service with the company through that vesting date, as stated in the award’s footnote disclosure.